Most Recent
Explosives company Dyno Nobel is appealing a court's dismissal of its case seeking to invalidate patents owned by rival Orica for a wireless detonation device.
Dyno Nobel has lost its bid to invalidate three of explosive manufacturer Orica’s patents for a wireless detonation device, with a judge finding it was liable for patent infringement.
The Full Court has upheld the cancellation of a US sports merchandise company's 'Fanatics' trade mark, agreeing it knew about Australian AFL merchandise maker FanFirm’s trade marks when it chose its name.
ASIC has succeeded in overturning a decision that found that Qoin issuer BPS Financial came within the authorised representative exemption with respect to agreements with Australian financial services licence holder PNI.
Construction PRO
Liquidators of collapsed builder Privium have won extra time to pursue potential proceedings over a number of suspicious transactions, which include unexplained payments to companies associated with a director.
The High Court will weigh in on the relevance of reputation in passing off claims, taking up an appeal by Bed Bath N’ Table of a finding that rival retailer House did not engage in misleading and deceptive conduct in setting up its Bed & Bath stores.
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis' appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
The High Court won't hear Bayer's appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company's claim the decision has "profound" consequences for drug R&D.
Otsuka Pharmaceuticals is challenging a decision revoking its patent for an injectable version of antipsychotic drug Abilify.
Generic drug maker Sun Pharma has succeeded in invalidating Otsuka Pharmaceutical’s patent for an injectable, controlled release form of the Japanese drug maker's top-selling antipsychotic Abilify.